Physician-Industry Interactions and Anti–Vascular Endothelial Growth Factor Use Among US Ophthalmologists
Open Access
- 1 August 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 134 (8) , 897-903
Abstract
In an effort to increase the transparency of physician-industry relationships, the Physician Payments Sunshine Act was signed into law in 2010 in the United States and mandates public posting of all payments to physicians by the pharmaceutical industry. The Physician Payments Sunshine Act registry began tracking industry payments to physicians beginning August 2013, and it provides unique insight into the financial relationship between physicians and industry in the United States. For example, during the last 5 months of 2013, a total of 470 000 US health care professionals received $3.4 billion in industry payments.1 Although this registry provides valuable understanding into the extent of physician-industry interactions, it does little to assess whether physician-industry relationships influence physician practice habits.Keywords
This publication has 26 references indexed in Scilit:
- A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degenerationBritish Journal of Ophthalmology, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2011
- Pharmacotherapy for Neovascular Age-Related Macular Degeneration: An Analysis of the 100% 2008 Medicare Fee-For-Service Part B Claims FileAmerican Journal of Ophthalmology, 2011
- Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) StudyOphthalmology, 2010
- Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic ReviewPLOS Medicine, 2010
- All Gifts Large and Small: Toward an Understanding of the Ethics of Pharmaceutical Industry Gift-GivingThe American Journal of Bioethics, 2010
- Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaOphthalmology, 2010
- A National Survey of Physician–Industry RelationshipsNew England Journal of Medicine, 2007
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006